Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Null Results in Brief

No Association of Polymorphisms in CYP17, CYP19, and HSD17-B1 with Plasma Estradiol Concentrations in 1,090 British Women

Ruth C. Travis, Michael Churchman, Sarah A. Edwards, Gillian Smith, Pia K. Verkasalo, C. Roland Wolf, Helga Wolf and Timothy J. Key
Ruth C. Travis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Churchman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah A. Edwards
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gillian Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pia K. Verkasalo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Roland Wolf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helga Wolf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy J. Key
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published December 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Introduction

The production of endogenous estradiol, and thus the risk of breast cancer, may be affected by functional polymorphisms in the genes coding for enzymes in the steroid biosynthesis pathway. Potentially important polymorphisms have been identified in three genes: CYP17, which encodes for a P450 enzyme that catalyzes 17α-hydroxylase and C17-20 lyase activities in the biosynthesis of androgens; CYP19, which encodes for aromatase, the enzyme involved in the conversion of androgens to estrogens; and HSD17-B1, which encodes for the 17β-hydroxysteroid oxidoreductase type 1 enzyme that reduces estrone to estradiol. Several studies have observedan association between risk for breast cancer and these polymorphisms (1). However, other studies have not found such an association, and the biological relationship of these polymorphisms with circulating estrogens has yet to be established. We assessed whether polymorphisms in CYP17, CYP19, or HSD17-B1 are associated with circulating levels of estradiol, the most biologically potent estrogen. Specifically, we examined a T to C substitution 34 bp upstream of the translation initiation site in the 5′ untranslated region of CYP17 among 634 premenopausal and 455 postmenopausal British women. Among the postmenopausal women, we also examined a [TTTA]n repeat allele beginning at bp 682 (intron 4) of CYP19, an associated TCT insertion/deletion polymorphism, a C to T substitution in the untranslated region of exon 10 of CYP19, and an A to G substitution in exon 6 of HSD17-B1 1,954 bp downstream of the first nucleotide in the translation initiation codon.

Materials and Methods

Study participants included 636 premenopausal and 456 postmenopausal British women recruited to the Oxford arm of the European Prospective Investigation into Cancer and Nutrition and previously studied in a cross-sectional analysis of sex hormones and risk factors for breast cancer (2, 3). Details of the estradiol assays are described elsewhere (2). One postmenopausal and two premenopausal women were excluded from the current study due to insufficient buffy coat being available for molecular analyses.

Genotyping on DNA extracted from buffy coat samples was conducted blind after the hormone assays had been completed. Eight hundred and ninety-eight samples were genotyped at the Cancer Research UK Genotyping Facility in Oxford. Blinded quality control samples (3.4%) were inserted to validate genotype identification procedures: concordance for the blinded samples was 100% for the CYP17 assay, 93.3% for the CYP19 intron 4 assay, 100% for the CYP19 exon 10 assay, and 100% for the HSD17-B1 assay. One hundred and ninety-eight samples were genotyped for the CYP17 single nucleotide polymorphism at the Biomedical Research Centre in Dundee as part of a previous unpublished study using similar methods. Genotype frequencies from the two laboratories were statistically similar: CYP17 TT, TC, and CC genotype frequencies were 40.0%, 45.9%, and 14.1%, respectively, for samples assayed in Oxford and 38.4%, 47.0%, and 14.7%, respectively, for samples assayed in Dundee (χ2 = 0.18, P = 0.9). Seven samples were genotyped for CYP17 at both laboratories and there was 100% concordance between the two sets of results.

Estradiol values were logarithmically transformed to reduce the positive skewness of the distributions, and geometric mean hormone values and the corresponding95% confidence intervals are presented. ANOVA was used to evaluate the association between genotypes andestradiol concentrations. Estradiol concentrations in postmenopausal women, classified by their number of putative high-risk alleles, including single nucleotide polymorphisms in CYP17, CYP19 exon 10, and HSD17-B1 were also examined. Statistical analyses were repeated with adjustment for potential confounders including age (5-year age groups), body mass index [calculated as weight/height2 (kg/m2) and grouped <20, 20<22.5, 22.5<25, 25<27.5, ≥27.5], vigorous exercise (0, 1-2, 3-4, ≥5 hours per week), and number of days the blood sample was in the post (0-1, 2, ≥3 days; among postmenopausal women only). In the analyses of data from premenopausal women, adjustment was also made for stage of menstrual cycle (early follicular, late follicular, mid-cycle, early luteal, and late luteal defined as ≥22, 16-21, 12-15, 3-11, and 0-2 days before next menstrual period), smoking status (never, former, current), alcohol consumption (<0.50, 0.50<8.0, 8.0<16.0, ≥16.0 g/d), and hours since last meal (0-1, 2, 3-4, ≥5 hours).

Results

There was no statistically significant variation in plasma estradiol concentrations by CYP17 genotype in premenopausal or postmenopausal women, either before or after adjustment for potential confounders. Table 1 shows the results from the multivariable model. We also found no association between CYP19 or HSD17-B1 variants and estradiol concentrations among postmenopausal women. When subjects were classified according to the number of putative high-risk alleles in CYP17, CYP19 exon 10, and HSD17-B1, we did not observe a significant dose-response relationship between estradiol concentrations and number of high-risk alleles, nor did we observe significant heterogeneity in estradiol concentrations by the number of high-risk alleles either before or after adjustment for potential confounders.

View this table:
  • View inline
  • View popup
Table 1.

Multivariable-adjusted geometric mean hormone levels by CYP17, CYP19, and HSD17-B1 genotypes

Discussion

The results of this study suggest that there is no association between plasma estradiol concentrations and a polymorphism in CYP17 in either premenopausal or postmenopausal women, in contrast with the findings of two early studies that found the same polymorphism to be significantly associated with estradiol concentrations (4, 5) but in agreement with several more recent investigations (6-10).

Aromatase, encoded by CYP19, catalyzes the last stage in estrogen production; therefore, the effects of variants of this gene are of particular interest in relation to plasma estradiol concentrations. Previous studies have found elevated estradiol concentrations in carriers of the CYP19 8-repeat allele (10, 11) and the longer repeat alleles (12 and 13 repeats; ref. 12) compared with noncarriers, and reduced estradiol levels in carriers of the 7-repeat allele (11) and the 3-bp deletion polymorphism (10), although associations reached statistical significance in only one study (10). Our results, however, suggest no association between these polymorphisms in CYP19 and plasma estradiol concentrations in postmenopausal women. Our null findings for the CYP19 exon 10 polymorphism in relation to estradiol concentrations are consistent with results from the only other study of this variant and estradiol (13).

Polymorphisms in the gene HSD17-B1 may also be important given the role of 17β-hydroxysteroid oxidoreductase type 1 in the reduction of estrone to the more biological potent estradiol, yet to the authors' knowledge, no previously published studies have investigated polymorphisms in this gene in relation to estradiol concentrations. We found no association between a polymorphism in this gene and estradiol concentrations in postmenopausal women. We also found no evidence that the effects of individual polymorphisms in genes involved in steroid biosynthesis were cumulative as has been suggested previously (14).

This study had >80% power at a 0.05 significance level to detect differences of 25% in plasma concentrations between women with different genotypes. The results suggest that there is no large effect of the polymorphisms studied in CYP17, CYP19, and HSD17-B1 on endogenous estradiol concentrations; however, more data would be needed to establish whether or not there is a small effect.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted May 20, 2004.
    • Received January 29, 2004.
    • Revision received April 29, 2004.

References

  1. ↵
    Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843–54.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Thomas HV, Davey GK, Key TJ. Oestradiol and sex hormone-binding globulin in premenopausal and post-menopausal meat-eaters, vegetarians and vegans. Br J Cancer 1999;80:1470–5.
    OpenUrlCrossRefPubMed
  3. ↵
    Verkasalo PK, Thomas HV, Appleby PN, Davey GK, Key TJ. Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom). Cancer Causes Control 2001;12:47–59.
    OpenUrlCrossRefPubMed
  4. ↵
    Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998;58:585–7.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Haiman CA, Hankinson SE, Spiegelman D, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999;59:1015–20.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 2001;61:3955–60.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Marszalek B, Lacinski M, Babych N, et al. Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5′-UTR in patients with polycystic ovarian syndrome. Gynecol Endocrinol 2001;15:123–8.
    OpenUrlPubMed
  8. ↵
    Garcia-Closas M, Herbstman J, Schiffman M, Glass A, Dorgan JF. Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer 2002;102:172–8.
    OpenUrlCrossRefPubMed
  9. ↵
    Somner J, McLellan S, Cheung J, et al. Polymorphisms in the P450 c17(17-hydroxylase/17,20-lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2004;89:344–51.
    OpenUrlCrossRefPubMed
  10. ↵
    Tworoger SS, Chubak J, Aiello EJ, et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:94–101.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Haiman CA, Hankinson SE, Spiegelman D, et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000;87:204–10.
    OpenUrlCrossRefPubMed
  12. ↵
    Berstein LM, Imyanitov EN, Suspitsin EN, et al. CYP19 gene polymorphism in endometrial cancer patients. J Cancer Res Clin Oncol 2001;127:135–8.
    OpenUrlCrossRefPubMed
  13. ↵
    Haiman CA, Hankinson SE, Spiegelman D, Brown M, Hunter DJ. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:215–6.
    OpenUrlFREE Full Text
  14. ↵
    Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 2001;61:785–9.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 13 (12)
December 2004
Volume 13, Issue 12
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
No Association of Polymorphisms in CYP17, CYP19, and HSD17-B1 with Plasma Estradiol Concentrations in 1,090 British Women
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
No Association of Polymorphisms in CYP17, CYP19, and HSD17-B1 with Plasma Estradiol Concentrations in 1,090 British Women
Ruth C. Travis, Michael Churchman, Sarah A. Edwards, Gillian Smith, Pia K. Verkasalo, C. Roland Wolf, Helga Wolf and Timothy J. Key
Cancer Epidemiol Biomarkers Prev December 1 2004 (13) (12) 2282-2284;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
No Association of Polymorphisms in CYP17, CYP19, and HSD17-B1 with Plasma Estradiol Concentrations in 1,090 British Women
Ruth C. Travis, Michael Churchman, Sarah A. Edwards, Gillian Smith, Pia K. Verkasalo, C. Roland Wolf, Helga Wolf and Timothy J. Key
Cancer Epidemiol Biomarkers Prev December 1 2004 (13) (12) 2282-2284;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Diet Quality and Ovarian Cancer Survival
  • PDE5 inhibitors use and precursors of colorectal cancer
  • Association between serum iron biomarkers and breast cancer
Show more Null Results in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement